395: Biotech investors' plea to Trump, and a busy M&A week

The biotech podcast episode centers on recent developments in the pharmaceutical industry, including the obesity drug market and mergers and acquisitions. It highlights the FDA's approval of Eli Lilly's new obesity pill, Foundayo, and the ensuing price competition with Novo Nordisk's Wigovi, also raising concerns about telehealth platforms potentially incentivizing prescriptions. The hosts also discuss Eli Lilly's acquisition of Sentesa Pharmaceuticals for sleep disorder treatments and Biogen's acquisition of Apellis Pharmaceuticals. Additionally, the episode covers the use of influencer marketing by psychedelic biotech companies and a letter from rare disease advocates urging the FDA to restore regulatory flexibility, featuring Rod Wong, managing partner at RTW Investments, who voices concerns about decreased investment in rare disease research due to regulatory unpredictability.